Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04428333
Title Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

hypopharynx cancer

oral cavity cancer

Therapies

Carboplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Facility Status City State Zip Country Details
GSK Investigational Site Duarte California 91010 United States Details
GSK Investigational Site Oro Verde Entre Ríos E3100XAD Argentina Details
GSK Investigational Site Rosario Santa Fe S2000DBS Argentina Details
GSK Investigational Site Ciudad Autonoma de Buenos Aires 1012 Argentina Details
GSK Investigational Site Ciudad Autónoma de Buenos Aires C1426ABP Argentina Details
GSK Investigational Site Blacktown New South Wales 2148 Australia Details
GSK Investigational Site Woolloongabba Queensland 4102 Australia Details
GSK Investigational Site Heidelberg Victoria 3084 Australia Details
GSK Investigational Site Melbourne Victoria 3000 Australia Details
GSK Investigational Site Bruxelles 1070 Belgium Details
GSK Investigational Site Edegem 2650 Belgium Details
GSK Investigational Site Vitória Espírito Santo 29043-260 Brazil Details
GSK Investigational Site Curitiba Paraná 81520-060 Brazil Details
GSK Investigational Site São Paulo 01246-000 Brazil Details
GSK Investigational Site Edmonton Alberta T6G 1Z2 Canada Details
GSK Investigational Site Hamilton Ontario L8V 5C2 Canada Details
GSK Investigational Site London Ontario N6A 4G5 Canada Details
GSK Investigational Site Toronto Ontario M4N 3M5 Canada Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Montreal Quebec H2X 3E4 Canada Details
GSK Investigational Site Koebenhavn Oe 2100 Denmark Details
GSK Investigational Site Bordeaux 33000 France Details
GSK Investigational Site Lyon cedex 08 69373 France Details
GSK Investigational Site Paris 75005 France Details
GSK Investigational Site Poitiers cedex 86021 France Details
GSK Investigational Site Strasbourg 67200 France Details
GSK Investigational Site Ulm Baden-Wuerttemberg 89075 Germany Details
GSK Investigational Site Hannover Niedersachsen 30625 Germany Details
GSK Investigational Site Leipzig Sachsen 04103 Germany Details
GSK Investigational Site Berlin 12203 Germany Details
GSK Investigational Site Dublin 8 Ireland Details
GSK Investigational Site Napoli Campania 80131 Italy Details
GSK Investigational Site Roma Lazio 00144 Italy Details
GSK Investigational Site Savona Liguria 17100 Italy Details
GSK Investigational Site Brescia Lombardia 25123 Italy Details
GSK Investigational Site Milano Lombardia 20132 Italy Details
GSK Investigational Site Milano Lombardia 20133 Italy Details
GSK Investigational Site Prato Toscana 59100 Italy Details
GSK Investigational Site Osaka 541-8567 Japan Details
GSK Investigational Site Osaka 589-8511 Japan Details
GSK Investigational Site Tokyo 104-0045 Japan Details
GSK Investigational Site Tokyo 135-8550 Japan Details
GSK Investigational Site Daegu-si 42601 Korea, Republic of Details
GSK Investigational Site Gyeonggi-do 10408 Korea, Republic of Details
GSK Investigational Site Hwasun-gun, Jeollanam-do 58128 Korea, Republic of Details
GSK Investigational Site Seoul 05505 Korea, Republic of Details
GSK Investigational Site Seoul 137-701 Korea, Republic of Details
GSK Investigational Site Bydgoszcz 85-796 Poland Details
GSK Investigational Site Gdynia 81-519 Poland Details
GSK Investigational Site Gliwice 44-102 Poland Details
GSK Investigational Site Lublin 20-090 Poland Details
GSK Investigational Site Tomaszow Mazowiecki 97-200 Poland Details
GSK Investigational Site Warszawa 02-781 Poland Details
GSK Investigational Site Bucuresti 021389 Romania Details
GSK Investigational Site Cluj Napoca 400015 Romania Details
GSK Investigational Site Craiova 200347 Romania Details
GSK Investigational Site Floresti 407280 Romania Details
GSK Investigational Site Otopeni 075100 Romania Details
GSK Investigational Site Suceava 720284 Romania Details
GSK Investigational Site Pushkin 196603 Russian Federation Details
GSK Investigational Site Barcelona 08035 Spain Details
GSK Investigational Site Madrid 28040 Spain Details
GSK Investigational Site Madrid 28041 Spain Details
GSK Investigational Site Madrid 28046 Spain Details
GSK Investigational Site Madrid 28050 Spain Details
GSK Investigational Site Valencia 46026 Spain Details
GSK Investigational Site Stockholm SE-171 64 Sweden Details
GSK Investigational Site London SW3 6JJ United Kingdom Details
GSK Investigational Site Nottingham NG5 1PB United Kingdom Details
GSK Investigational Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field